- Dry Eye
- Macular Deg
Animal Clinical Trials Prove Can-C™ Safe and Effective “A new phenomenon of “melting snow” in only a few short weeks…
The testing of various anti-glycation agents over nearly a decade led a Russian research team to the development of n-alpha-acetylcarnosine as a delivery system for the natural eye anti-oxidant of L-carnosine.
Study finds that Melatonin also offers a promising role in the safe treatment and management of Glaucoma
“Data indicates that melatonin, being an efficient antioxidant with antinitridergic properties, has a promising role in the treatment and management of glaucoma.”
Dry Eye type II is has been defined to be characterized by clinically-evident inflammation, and clear evidence of epithelial alterations. Type III Dry Eye is a chronic form with accompanied by clinically-evident and chronic inflammation.
Study finds that Dry Eye Disease (DED) progression may be delayed by breaking the chronic cycle of ocular surface inflammation
The purpose of this article is to review the evidence for the hypothesis that the core mechanism of Dry Eye Disease (DED) is inflammation, including evidence from recent basic, clinical and translational research involving human patients, animal models, and cell cultures.
In clinical test NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared to control at 4-months
1% N-acetylcarnosine (NAC) eye drops were applied topically to the eyes of older drivers. Study results provide a substantial basis for further evaluation of NAC in the treatment and prevention of vision impairment …
The majority had reduced pathologic macular changes. We conclude that the daily use of 3 mg melatonin seems to protect the retina and to delay macular degeneration. No significant side effects were observed…